var data={"title":"Vitamin B6 (pyridoxine): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vitamin B6 (pyridoxine): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6879?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vitamin-b6-pyridoxine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vitamin B6 (pyridoxine): Patient drug information&quot;</a> and <a href=\"topic.htm?path=vitamin-b6-pyridoxine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vitamin B6 (pyridoxine): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216001\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Neuro-K-250 T.D. [OTC];</li>\n      <li>Neuro-K-250 Vitamin B6 [OTC];</li>\n      <li>Neuro-K-50 [OTC];</li>\n      <li>Neuro-K-500 [OTC];</li>\n      <li>Pyri 500 [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216041\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vitamin, Water Soluble</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216003\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pyridoxine deficiency:</b> IM, IV: 10 to 20 mg/day for 3 weeks, followed by daily oral therapy for several weeks. Doses up to 600 mg/day may be needed with pyridoxine dependency syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gyromitrin-containing mushroom (false morel) overdose/toxicity (treatment/prophylaxis) (off-label use):</b> IV: 25 mg/kg over 15 to 30 minutes; repeat dose as needed to control seizures (Diaz 2005; Lheureux 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nausea and vomiting of pregnancy (off-label use): </b>Oral: 10 to 25 mg every 8 hours (Neibyl 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neurological toxicities (ie, seizures, coma) associated with isoniazid overdose (prevention) (off-label use):</b> IV: Asymptomatic patients who present within 2 hours of ingesting a potentially toxic amount of isoniazid should receive a prophylactic dose of pyridoxine (Hernon 2015). Dosing recommendations are the same as for the treatment of symptomatic patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neurological toxicities (ie, seizures, coma) associated with isoniazid overdose (treatment) (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute ingestion of known amount:</i> Initial: A total dose of pyridoxine equal to the amount of isoniazid ingested (maximum dose: 5 g); administer at a rate of 0.5 to 1 g/minute until seizures stop or the maximum initial dose has been administered; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity. If seizures stop prior to the administration of the calculated initial dose, infuse the remaining pyridoxine over 4 to 6 hours (Howland 2015; Morrow 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute ingestion of unknown amount:</i> Initial: 5 g; administer at a rate of 0.5 to 1 g/minute; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland 2015; Morrow 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral neuropathy associated with isoniazid therapy for</b> <b><i>Mycobacterium tuberculosis</i></b><b> (prevention):</b> Oral: 25 to 50 mg/day (CDC [Kaplan 2009]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216023\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=vitamin-b6-pyridoxine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Vitamin B6 (pyridoxine): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gyromitrin-containing mushroom (false morel) overdose/toxicity (treatment/prophylaxis) (off-label use):</b> IV: Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neurological toxicities (ie, seizures, coma) associated with isoniazid overdose (prevention) (off-label use):</b> IV: Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neurological toxicities (ie, seizures, coma) associated with isoniazid overdose (treatment) (off-label use):</b> IV: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute ingestion of known amount:</i> Initial: A total dose of pyridoxine equal to the amount of isoniazid ingested (maximum dose: 70 mg/kg, up to 5 g); administer at a rate of 0.5 to 1 g/minute until seizures stop or the maximum initial dose has been administered; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity. If seizures stop prior to the administration of the calculated initial dose, infuse the remaining pyridoxine over 4 to 6 hours (Howland 2015; Morrow 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute ingestion of unknown amount:</i> Initial: 70 mg/kg (maximum dose: 5 g); administer at a rate of 0.5 to 1 g/minute; may repeat every 5 to 10 minutes as needed to control persistent seizure activity and/or CNS toxicity (Howland 2015; Morrow 2006; Santucci 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216004\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49076773\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49076774\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215977\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuro-K-250 T.D.: 250 mg [corn free, rye free, starch free, sugar free, wheat free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuro-K-50: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuro-K-500: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuro-K-250 Vitamin B6: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pyri 500: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg, 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215962\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215982\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Administer IM or IV.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gyromitrin-containing mushroom (false morel) overdose/toxicity (treatment/prophylaxis) (off-label use): Administer dose over 15 to 30 minutes (Lheureux 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid toxicity (off-label use): Initial doses should be administered at a rate of 0.5 to 1 g/minute. If the parenteral formulation is not available, anecdotal reports suggest that pyridoxine tablets may be crushed and made into a slurry and given at the same dose orally or via nasogastric (NG) tube (Hernon 2015). Oral administration is not recommended for acutely poisoned patients with seizure activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215981\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Pyridoxine deficiency: </b>Treatment and prevention of pyridoxine (vitamin B<sub>6</sub>) deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744561\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Gyromitrin-containing mushroom (false morel) overdose/toxicity (treatment/prophylaxis); Nausea and vomiting of pregnancy; Neurological toxicities (ie, seizures, coma) associated with isoniazid  overdose (prevention); Neurological toxicities (ie, seizures, coma) associated with isoniazid overdose (treatment); Peripheral neuropathy associated with isoniazid therapy for Mycobacterium tuberculosis (prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216049\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pyridoxine may be confused with paroxetine, pralidoxime, Pyridium</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doxal [Brazil] may be confused with Doxil brand name for DOXOrubicin [U.S.]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doxal: Brand name for pyridoxine/thiamine combination [Brazil], but also the brand name for doxepin [Finland]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215969\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Ataxia, drowsiness, headache, neuropathy, paresthesia, seizure (following very large IV doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, folate deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215986\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pyridoxine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215966\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropathy: Severe, permanent peripheral neuropathies have been reported; neurotoxicity is more common with long-term administration of large doses (&gt;2 g/day) (Albin 1987).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal impairment. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dependence/withdrawal: Doses &gt;200 mg/day may cause dependence and withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pharmacy supply of emergency antidotes: Guidelines suggest that at least 8 to 24 g be stocked. This is enough to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period. In areas where tuberculosis is common and isoniazid toxicity is more likely, hospitals should consider stocking 24 g. This is enough to treat 1 patient for 24 hours (Dart 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin deficiency: Single vitamin deficiency is rare; evaluate for other deficiencies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299968\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215971\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9839&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Altretamine: Pyridoxine may diminish the therapeutic effect of Altretamine. Specifically when altretamine is used in combination with Cisplatin the response duration may be diminished. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: Pyridoxine may increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day) <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Pyridoxine may increase the metabolism of Fosphenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily) <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Pyridoxine may diminish the therapeutic effect of Levodopa.  Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Pyridoxine may increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily) <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215974\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">A (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215989\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Water soluble vitamins cross the placenta. Maternal pyridoxine plasma concentrations may decrease as pregnancy progresses and requirements may be increased in pregnant women (IOM 1998). Pyridoxine is used to treat nausea and vomiting of pregnancy (Neibyl 2010). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215990\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pyridoxine is found in breast milk and concentrations vary by maternal intake. Pyridoxine requirements are increased in nursing women compared to non-nursing women (IOM 1998). Possible inhibition of lactation at doses &gt;600 mg/day when taken immediately postpartum (Foukas 1973). The manufacturer recommends that caution be exercised when administering pyridoxine injection to breast-feeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50930847\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dietary adequate Intake (AI) (IOM 1998): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 6 months: 0.1 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">7 to 12 months: 0.3 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dietary recommended daily allowance (RDA) (IOM 1998):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 3 years: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">4 to 8 years: 0.6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">9 to 13 years: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">14 to 18 years: Females: 1.2 mg; Males: 1.3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">19 to 50 years: 1.3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;51 years: Females: 1.5 mg; Males: 1.7 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pregnancy: 1.9 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lactation: 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5509499\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">For treatment of isoniazid or gyromitrin-containing mushroom toxicity: Anion gap, arterial blood gases, electrolytes, neurological exam, seizure activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215978\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Over 50 ng/mL (SI: 243 nmol/L) (varies considerably with method). A broad range is ~25-80 ng/mL (SI: 122-389 nmol/L). HPLC method for pyridoxal phosphate has normal range of 3.5-18 ng/mL (SI: 17-88 nmol/L).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215965\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Precursor to pyridoxal, which functions in the metabolism of proteins, carbohydrates, and fats; pyridoxal also aids in the release of liver and muscle-stored glycogen and in the synthesis of GABA (within the central nervous system) and heme</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215985\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Well absorbed (IOM 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic to pyridoxal phosphate and pyridoxamine phosphate (active forms)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Biologic: 15 to 20 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215988\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Neuro-K-250 T.D. Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $9.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pyridoxine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (1 mL): $18.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pyridoxine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1000): $11.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $8.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $5.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215991\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AFI-B6 (NO);</li>\n      <li>B(6)-Vicotrat (DE);</li>\n      <li>Becilan (FR);</li>\n      <li>Bedoxine (BE, LU);</li>\n      <li>Bedoyecta (MX);</li>\n      <li>Beesix (ZA);</li>\n      <li>Benadon (AR, AT, CH, ES, GB, IE, IT, PT, SE);</li>\n      <li>Bexivit (GR);</li>\n      <li>Biprin (CO);</li>\n      <li>Bivit (IT);</li>\n      <li>Burgerstein Vitamin B6 (CH);</li>\n      <li>Comploment Continus (AE, BH, CH, CY, EG, IE, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Dermo 6 (FR);</li>\n      <li>Dodemina (MX);</li>\n      <li>Dolvifen (MX);</li>\n      <li>Farmobion B6 (IT);</li>\n      <li>Glutarase (IT);</li>\n      <li>Heksavit (FI);</li>\n      <li>Hexobion 100 (DE);</li>\n      <li>Hysix (JP);</li>\n      <li>Incremin con hierro (MX);</li>\n      <li>M. V. I. 12 (MX);</li>\n      <li>Memosprint (IT);</li>\n      <li>Natele (MX);</li>\n      <li>Nuro-B (MX);</li>\n      <li>Pharmaton (MX);</li>\n      <li>Pidopidon (JP);</li>\n      <li>Piridoxina Austral (AR);</li>\n      <li>Plivit B6 (HR);</li>\n      <li>Poly-B con Vitamina C (MX);</li>\n      <li>Pyricontin Continus (IN);</li>\n      <li>Pyridoxin Recip[Tab.] (SE);</li>\n      <li>Pyridoxin &rdquo;Dak&rdquo; (DK);</li>\n      <li>Pyridoxine Aguettant (FR);</li>\n      <li>Pyridoxine Renaudin (FR);</li>\n      <li>Pyridoxine-Labaz (LU);</li>\n      <li>Pyrivitol (AT);</li>\n      <li>Pyroxin (AU);</li>\n      <li>Reisevit (AT);</li>\n      <li>Sechvitan (JP);</li>\n      <li>Tanvimil B6 (AR);</li>\n      <li>Trineurovita (MX);</li>\n      <li>Vit. B6 Agepha (AT);</li>\n      <li>Vita-B6 (FI);</li>\n      <li>Vitamin B6 (HU);</li>\n      <li>Vitamin B6 Streuli (CH);</li>\n      <li>Vitamine B6 Richard (FR);</li>\n      <li>Vitaminum B6 (PL);</li>\n      <li>Xanturenasi (IT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Albin RL, Albers JW, Greensberg HS, et al, &ldquo;Acute Sensory Neuropathy - Neuronopathy From Pyridoxine Overdose,&rdquo; <i>Neurology</i>, 1987, 37(11):1729-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/2823181/pubmed\" target=\"_blank\" id=\"2823181\">2823181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR &sect;201.323.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baxter P, &quot;Epidemiology of Pyridoxine Dependent and Pyridoxine Responsive Seizures in the UK,&quot; <i>Arch Dis Child</i>, 1999, 81(5):431-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/10519720/pubmed\" target=\"_blank\" id=\"10519720\">10519720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chase P, Walter F, Vandenberghe D, et al, &ldquo;Pyridoxine Does Not Prevent Hyperbaric Oxygen Toxicity Seizures in Rats,&rdquo; <i>Clin Toxicol</i>, 1995, 33(5):531.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dart RC, Borron SW, Caravati EM, et al,&ldquo;Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care,&rdquo; <i>Ann Emerg Med</i>, 2009, 54(3):386-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/19406507/pubmed\" target=\"_blank\" id=\"19406507\">19406507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Zegher FD, Przyrembel H, Chalmers RA, et al, &ldquo;Successful Treatment on Infantile Type I Primary Hyperoxaluria Complicated by Pyridoxine Toxicity,&rdquo; <i>Lancet</i>, 1985, 2(8451):392-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15699849\"></a>Diaz JH, &ldquo;Syndromic Diagnosis and Management of Confirmed Mushroom Poisonings,&rdquo; <i>Crit Care Med</i>, 2005, 33(2):427-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/15699849/pubmed\" target=\"_blank\" id=\"15699849\">15699849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foukas MD, &quot;An Antilactogenic Effect of Pyridoxine,&quot; <i>J Obstet Gynaecol BrCommonw</i>, 1973, 80(8):718-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/4579974/pubmed\" target=\"_blank\" id=\"4579974\">4579974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glenn GM, Krober MS, Kelly P, et al, &ldquo;Pyridoxine as Therapy in Theophylline-Induced Seizures,&rdquo; <i>Vet Hum Toxicol</i>, 1995, 37(4):342-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/8540225/pubmed\" target=\"_blank\" id=\"8540225\">8540225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greentree LB, &quot;Inhibition of Prolactin by Pyridoxine,&quot; <i>Am J Obstet Gynecol</i>, 1979, 135(2):280-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/474683/pubmed\" target=\"_blank\" id=\"474683\">474683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harati Y and Niakan E, &ldquo;Hydrazine Toxicity, Pyridoxine Therapy, and Peripheral Neuropathy,&rdquo; <i>Ann Intern Med</i>, 1986, 104(5):728-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Hernon.2015\"></a>Hernon CH. Antituberculous Medications. In: Hoffman RS, Howland M, Lewin NA, Nelson LS, Goldfrank LR, eds. <i>Goldfrank's Toxicologic Emergencies, 10e</i>. New York, NY: McGraw-Hill; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Howland.2015\"></a>Howland MA, &ldquo;Antidotes in Depth: Pyridoxine,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 10th ed, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2015, 872-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B</i><sub>6</sub><i>, Folate, Vitamin B</i><sub>12</sub><i>, Pantothenic Acid, Biotin, and Choline</i>, Washington, DC: The National Academies Press, 1998.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kajiyama Y, Fujii K, Takeuchi H, et al, &ldquo;Ginko Seed Poisoning,&rdquo; <i>Pediatrics</i>, 2002, 109(2):325-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/11826216/pubmed\" target=\"_blank\" id=\"11826216\">11826216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <i>MMWR Recomm Rep</i>. 2009;58(RR-4):1-207; quiz CE1-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/19357635/pubmed\" target=\"_blank\" id=\"19357635\">19357635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. <i>Eur J Emerg Med</i>. 2005;12(2):78-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/15756083/pubmed\" target=\"_blank\" id=\"15756083\">15756083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LoVecchio F, Curry SC, Graeme KA, et al, &ldquo;Intravenous Pyridoxine-Induced Metabolic Acidosis,&rdquo; <i>Ann Emerg Med</i>, 2001 38(1):62-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/11423814/pubmed\" target=\"_blank\" id=\"11423814\">11423814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16999664\"></a>Morrow LE, Wear RE, Schuller D, et al, &quot;Acute Isoniazid Toxicity and the Need for Adequate Pyridoxine Supplies,&quot; <i>Pharmacotherapy</i>, 2006, 26(10):1529-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/16999664/pubmed\" target=\"_blank\" id=\"16999664\">16999664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nagappan R and Riddell T, &ldquo;Pyridoxine Therapy in a Patient With Severe Hydrazine Sulfate Toxicity,&rdquo; <i>Crit Care Med</i>, 2000, 28(6):2116-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/10890675/pubmed\" target=\"_blank\" id=\"10890675\">10890675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20942670\"></a>Niebyl JR, &quot;Clinical Practice. Nausea and Vomiting in Pregnancy,&quot; <i>N Engl J Med</i>, 2010, 363(16):1544-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/20942670/pubmed\" target=\"_blank\" id=\"20942670\">20942670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orlowski JP, Paganini EP, Pippenger CE, et al, &ldquo;Treatment of a Potentially Lethal Dose Isoniazid Ingestion,&rdquo; <i>Ann Emerg Med</i>, 1988, 17(1):73-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/3337420/pubmed\" target=\"_blank\" id=\"3337420\">3337420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pauling L, &ldquo;Sensory Neuropathy From Pyridoxine Abuse,&rdquo; <i>N Engl J Med</i>, 1984, 310(3):197-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/6318110/pubmed\" target=\"_blank\" id=\"6318110\">6318110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pyridoxine injection [prescribing information]. Rockford, IL: Mylan Institutional LLC; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santucci KA, Shah BR, and Linakis JG, &quot;Acute Isoniazid Exposures and Antidote Availability,&quot; <i>Pediatric Emergency Care</i>, 1999, 15(2):99-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/10220077/pubmed\" target=\"_blank\" id=\"10220077\">10220077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scharman EJ and Rosencrane JG, &ldquo;Isoniazid Toxicity: A Survey of Pyridoxine Availability,&rdquo; <i>Am J Emerg Med</i>, 1994, 12(3):386-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schnyder G, Roffi M, Flammer Y, et al, &ldquo;Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Clinical Outcome After Percutaneous Coronary Intervention: The Swiss Heart Study: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2002, 288(8):973-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b6-pyridoxine-drug-information/abstract-text/12190367/pubmed\" target=\"_blank\" id=\"12190367\">12190367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vitamin B6 [prescribing information]. Long Island City: NY: Freeda Vitamins Inc; rcvd June 2011.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9839 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F216001\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F216041\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F216003\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F216023\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F216004\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F49076773\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F49076774\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F215977\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F215962\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F215982\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F215981\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744561\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F216049\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F215969\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F215986\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F215966\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299968\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F215971\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F215974\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F215989\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F215990\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F50930847\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5509499\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F215978\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F215965\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F215985\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F215988\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F215991\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9839|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vitamin-b6-pyridoxine-patient-drug-information\" class=\"drug drug_patient\">Vitamin B6 (pyridoxine): Patient drug information</a></li><li><a href=\"topic.htm?path=vitamin-b6-pyridoxine-pediatric-drug-information\" class=\"drug drug_pediatric\">Vitamin B6 (pyridoxine): Pediatric drug information</a></li></ul></div></div>","javascript":null}